William Blair & Company
TEVA icon

William Blair & Company’s Teva Pharmaceuticals TEVA Stock Holding History

William Blair & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$425K Buy
14,104
+251
+2% +$8.07K ﹤0.01% 1202
2025
Q4 		$432K Sell
13,853
-4,585
-25% -$113K ﹤0.01% 1192
2025
Q3 		$372K Sell
18,438
-162
-0.9% -$2.85K ﹤0.01% 1223
2025
Q2 		$312K Sell
18,600
-182
-1% -$2.94K ﹤0.01% 1247
2025
Q1 		$289K Buy
18,782
+7,550
+67% +$135K ﹤0.01% 1273
2024
Q4 		$248K Buy
11,232
+963
+9% +$17.5K ﹤0.01% 1360
2024
Q3 		$185K Sell
10,269
-236
-2% -$4.13K ﹤0.01% 1453
2024
Q2 		$171K Buy
10,505
+118
+1% +$1.82K ﹤0.01% 1443
2024
Q1 		$147K Sell
10,387
-73
-0.7% -$920 ﹤0.01% 1458
2023
Q4 		$109K Sell
10,460
-440
-4% -$4.11K ﹤0.01% 1495
2023
Q3 		$111K Buy
10,900
+130
+1% +$1.21K ﹤0.01% 1491
2023
Q2 		$81.1K Sell
10,770
-18
-0.2% -$146 ﹤0.01% 1537
2023
Q1 		$95.5K Buy
10,788
+38
+0.4% +$376 ﹤0.01% 1510
2022
Q4 		$98K Sell
10,750
-300
-3% -$2.62K ﹤0.01% 1493
2022
Q3 		$89K Sell
11,050
-3,650
-25% -$32.3K ﹤0.01% 1520
2022
Q2 		$111K Hold
14,700
– – ﹤0.01% 1524
2022
Q1 		$138K Sell
14,700
-2,382
-14% -$19.9K ﹤0.01% 1593
2021
Q4 		$137K Sell
17,082
-1,268
-7% -$11.4K ﹤0.01% 1649
2021
Q3 		$179K Hold
18,350
– – ﹤0.01% 1522
2021
Q2 		$182K Sell
18,350
-500
-3% -$5.29K ﹤0.01% 1526
2021
Q1 		$218K Sell
18,850
-838
-4% -$9.61K ﹤0.01% 1454
2020
Q4 		$190K Sell
19,688
-24,827
-56% -$238K ﹤0.01% 1455
2020
Q3 		$401K Sell
44,515
-1,950
-4% -$20.6K ﹤0.01% 1036
2020
Q2 		$573K Sell
46,465
-182
-0.4% -$2.06K ﹤0.01% 894
2020
Q1 		$419K Buy
46,647
+1,481
+3% +$15.2K ﹤0.01% 914
2019
Q4 		$443K Buy
+45,166
New +$403K ﹤0.01% 1033
2019
Q2 		– Sell
-95,458
Closed -$1.5M – 1769
2019
Q1 		$1.5M Sell
95,458
-21,943
-19% -$387K 0.01% 632
2018
Q4 		$1.81M Buy
117,401
+20,836
+22% +$427K 0.01% 542
2018
Q3 		$2.08M Buy
96,565
+37,215
+63% +$864K 0.01% 548
2018
Q2 		$1.44M Sell
59,350
-6,841
-10% -$140K 0.01% 621
2018
Q1 		$1.13M Sell
66,191
-986
-1% -$19.3K 0.01% 683
2017
Q4 		$1.27M Sell
67,177
-10,626
-14% -$160K 0.01% 681
2017
Q3 		$1.37M Buy
77,803
+188
+0.2% +$4.23K 0.01% 641
2017
Q2 		$2.58M Buy
77,615
+2,472
+3% +$76.5K 0.02% 512
2017
Q1 		$2.63M Buy
75,143
+66,654
+785% +$2.27M 0.02% 473
2016
Q4 		$308K Sell
8,489
-2,245
-21% -$89.6K ﹤0.01% 993
2016
Q3 		$494K Sell
10,734
-13,219
-55% -$690K ﹤0.01% 838
2016
Q2 		$1.2M Sell
23,953
-4,636
-16% -$247K 0.01% 585
2016
Q1 		$1.53M Sell
28,589
-5,447
-16% -$320K 0.01% 514
2015
Q4 		$2.23M Sell
34,036
-68,739
-67% -$4.25M 0.02% 444
2015
Q3 		$5.8M Sell
102,775
-5,365,082
-98% -$348M 0.05% 296
2015
Q2 		$323M Sell
5,467,857
-57,336
-1% -$3.54M 0.48% 24
2015
Q1 		$344M Buy
5,525,193
+609,194
+12% +$35.4M 0.53% 15
2014
Q4 		$283M Buy
4,915,999
+18,366
+0.4% +$1.02M 0.46% 27
2014
Q3 		$263M Buy
4,897,633
+4,634,189
+1,759% +$246M 0.45% 33
2014
Q2 		$13.8M Sell
263,444
-3,790
-1% -$194K 0.02% 736
2014
Q1 		$14.1M Sell
267,234
-227,523
-46% -$10.5M 0.02% 703
2013
Q4 		$19.8M Buy
494,757
+175,711
+55% +$6.92M 0.03% 544
2013
Q3 		$12.1M Buy
319,046
+8,214
+3% +$320K 0.02% 678
2013
Q2 		$12.2M Buy
+310,832
New +$12.1M 0.02% 638

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair & Company's TEVA Position: Q1 2026 in Review

William Blair & Company increased its Teva Pharmaceuticals (TEVA) stake by 1.8% in Q1 2026, buying an estimated $8.07K and bringing the position to 14,104 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #1202.

William Blair & Company first reported a position in TEVA in Q2 2013 and has held it in 50 quarters since. The position peaked at $344M in Q1 2015. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • William Blair & Company held 14,104 shares of Teva Pharmaceuticals worth $425K as of Q1 2026.
  • William Blair & Company bought 251 Teva Pharmaceuticals shares in Q1 2026, an estimated $8.07K.
  • Teva Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1202 holding.
  • William Blair & Company first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • William Blair & Company's Teva Pharmaceuticals position peaked at $344M in Q1 2015.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.